home
about the project
News of medicine
Authors
Licensed books on medicine
<< Previous Next >>

Hypertrophic cardiomyopathy



Hypertrophic CMP is expressed by hypertrophy of the left ventricle and interventricular septum.

Clinical manifestations. More often in boys, there are family forms, shortness of breath, pain in the heart, widening the boundaries of the heart, weakening of the I tone at the top, accent of the second tone over the pulmonary artery, changeable systolodystolic murmur on the left side of the sternum, development of cardiovascular insufficiency in the left ventricular type.

Diagnostics. ECG - signs of hypertrophy of the left atrium and left ventricle; tooth Q changed in II-III ana., V4, V6. Echocardiography is a thickening of the interventricular septum, a decrease in the volume of the left ventricle. X-ray examination of the chest - depends on the size of the heart, the displacement of the mitral valve forward.

Carnitine CMP.

Hypertrophy of the ventricles: KDDlzh = 65 mm, atriomegaly, PV = 0.2, mitral regurgitation of the 2-3rd degree.

Treatment.
Surgical - septal myoectomy.

1. Valve replacement - two-chamber constant stimulation.

2. Conservative:

1) restriction of physical activity;

2) diet with restriction of salt and water;

3) b-adrenoblockers;

4) Ca-channel blockers;

5) antiarrhythmics of other groups;

6) ACE inhibitors.

Cardiac glycosides in HCM are contraindicated.

<< Previous Next >>
= Skip to the content of the tutorial =

Hypertrophic cardiomyopathy

  1. Cardiomyopathy. Hypertrophic cardiomyopathy (cipher 142.0)
    The term "cardiomyopathy" refers to the state of unknown etiology, the most important signs of which are cardiomegaly and heart failure; From this name, heart diseases that result from damage to the valves, coronary artery disease, hypertension of the large and small circle of circulation are excluded. Etiology. Clinical and anatomical forms. Proposed
  2. Hypertrophic cardiomyopathy
    HYPERTROPHIC CARDIOMYOPATHY - a disease of the myocardium of unknown etiology, manifested by hypertrophy of the left ventricle (mainly interventricular septum) without its dilatation. ETIOLOGY. Hypertrophic cardiomyopathy is characterized by primary hypertrophy of cardiomyocytes, not associated with increased cardiac function. Approximately 1/3 of patients with hypertrophic cardiomyopathy
  3. 5. HYPERTROPHIC CARDIOMYOPATHY
    General information Hypertrophic cardiomyopathy (HCMC) can be hereditary (penetrance varies) or sporadic. Synonyms: idiopathic hypertrophic subaortal stenosis, asymmetric septal hypertrophy, hypertrophic obstructive cardiomyopathy, and muscular subaortic stenosis. The disease is characterized by heterogeneous LV hypertrophy for no apparent reason.
  4. Cardiomyopathy is hypertrophic, dilated in children
    Protocol code: 05-057a Profile: pediatric Stage: hospital The purpose of the stage: 1. reducing the symptoms of circulatory insufficiency; 2. stabilization of hemodynamics; 3. development of basic maintenance therapy; 4. differential diagnosis with carditis. 5. Improvement of cardiac activity by clinical and instrumental (ECG, radiography, echocardiogram) criteria. Duration of treatment
  5. Hypertrophic cardiomyopathy
    It is known that in patients with hypertrophic cardiomyopathy there is a very high probability of fainting and sudden death. Holter monitoring is used as a tool for assessing the frequency and severity of ventricular arrhythmias in this group of patients. According to Magop et al. [52], 66% (out of 99) of the examined or patients had ventricular rhythm disturbances of "high gradations"
  6. VT with hypertrophic cardiomyopathy
    In the literature, various data on the frequency of VT in patients with hypertrophic cardiomyopathy are given: from 17.4% [Suyama A. et al., 1986] to 44.6% [Neri R. et al., 1987]. W. McKenna, A. Kleinebenne (1985) observed 135 episodes of VT in 30 of 100 patients. The duration of ECG recording averaged 6 days (from 1 to 15 days). Attacks were unstable: from 3 to 27 complexes (an average of 8), the frequency
  7. Hypertrophic cardiomyopathy
    Hypertrophic cardiomyopathy (HCMC) is characterized by massive ventricular hypertrophy (predominantly left ventricular) and pronounced diastolic dysfunction. Hypertrophy of the left ventricular wall more than 15 mm of unknown origin is considered a diagnostic criterion of HCM. There are obstructive (narrowing output of the left ventricle) and non-obstructive HCM. Hypertrophy may be symmetrical
  8. Treatment of hypertrophic cardiomyopathy
    The main tasks of HCMC treatment are: - providing symptomatic improvement and prolonging the life of patients by correcting the leading pathophysiological mechanisms of cardiohemodynamics disturbance; - a decrease in the severity of pathological hypertrophy of the myocardium as the main morphological substrate of HCMC, or at least preventing its further growth; - treatment and
  9. HYPERTROPHIC CARDIOMYOPATHY
    - a primary disease of the myocardium of unknown etiology, manifested by asymmetric hypertrophy of the left ventricle myocardium in the absence of dilatation of its cavity and the causes of hypertrophy of the cardiac muscle. The age of patients varies from 1 to 70 years, averaging 42 years. Among patients with HCMC, males predominate, the ratio of males to females is approximately 2: 1.
  10. Hypertrophic cardiomyopathy
    Hypertrophic
  11. HYPERTROPHIC CARDIOMYOPATHY
    Definition of HCMC - primary myocardial damage caused by the genetic inferiority of contractile proteins, is characterized by LVH in the absence of cardiac or systemic causes. Epidemiology Widespread among many racial groups in Europe, the United States, Canada, Israel, South America and the Far East. In the general population, its prevalence is 0.2% and there is
  12. Hypertrophic cardiomyopathy
    DEFINITION HCMC is characterized by hypertrophy of the left or right ventricle with diffuse or segmental thickening of their walls and interventricular septum. In this case, the left ventricular cavity is normal or reduced. This condition may be accompanied by a violation of the systolic or diastolic function of the ventricles. SCREENING Taking into account the fact that HCMC, in most cases, has
  13. Diagnosis of hypertrophic cardiomyopathy
    New research methods that have emerged in cardiology in recent years, such as the Doppler study of the heart, magnetic resonance imaging and positron emission tomography, have greatly expanded the possibilities of diagnosing HCMC and assessing the pathophysiological changes in this disease in clinical practice, which is important for optimizing treatment . Due to success in decoding
  14. Diagnostic criteria for hypertrophic cardiomyopathy
    Since strictly specific diagnostic features of HCMC, other than genetic, does not exist, this diagnosis can be established only with a greater or lesser degree of probability. Currently, in clinical practice, it is based on the detection of myocardial hypertrophy of the left and rarely right ventricles, which can not be explained by the presence of other cardiac or systemic diseases and not
  15. Pathophysiological mechanisms of hypertrophic cardiomyopathy
    The main pathophysiological mechanisms of HCM, mainly due to left ventricular hypertrophy and determining the course of the disease, include: 1. Changes in systolic function of the left ventricle; 2. Formation of a dynamic pressure gradient in the cavity of the left ventricle; 3. Disorders of diastolic properties of the left ventricle; 4. Ischemia of the myocardium; 5. Changes
  16. Pathological anatomy of hypertrophic cardiomyopathy
    When macroscopic examination of the heart draws attention to the significant hypertrophy of the left ventricular myocardium in the absence of morphological signs of congenital and acquired heart defects, IHD, systemic arterial hypertension and other diseases that can cause the development of such hypertrophy. The thickness of the left ventricle is often 35-45 mm (V. Maron, 1993). Have
Medical portal "MedguideBook" © 2014-2016
info@medicine-guidebook.com